(0.02%) 5 071.63 points
(-0.11%) 38 461 points
(0.10%) 15 713 points
(-0.19%) $82.65
(0.60%) $1.663
(-0.31%) $2 331.10
(-0.24%) $27.28
(-0.25%) $913.50
(0.01%) $0.935
(0.04%) $10.99
(0.05%) $0.803
(0.02%) $92.34
@ $7.30
Issued: 14 Feb 2024 @ 15:45
Return: -42.29%
Previous signal: Feb 14 - 12:33
Previous signal:
Return: 4.66 %
Live Chart Being Loaded With Signals
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma...
Stats | |
---|---|
Today's Volume | 2.72M |
Average Volume | 1.53M |
Market Cap | 760.11M |
EPS | $0 ( 2024-03-14 ) |
Next earnings date | ( $-0.100 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.51 |
ATR14 | $0.0140 (0.33%) |
Volume Correlation
Autolus Therapeutics PLC Correlation
10 Most Positive Correlations | |
---|---|
PBTS | 0.943 |
OP | 0.94 |
FLGC | 0.938 |
FNCH | 0.922 |
NNOX | 0.919 |
ALBO | 0.916 |
WKSP | 0.915 |
POWL | 0.912 |
NBSE | 0.91 |
DMRC | 0.907 |
10 Most Negative Correlations | |
---|---|
PRAA | -0.919 |
DTEA | -0.879 |
AVID | -0.875 |
FCCO | -0.873 |
PINC | -0.863 |
IEP | -0.856 |
PEBK | -0.854 |
PARA | -0.853 |
TUEM | -0.851 |
FOXF | -0.849 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Autolus Therapeutics PLC Correlation - Currency/Commodity
Autolus Therapeutics PLC Financials
Annual | 2023 |
Revenue: | $1.70M |
Gross Profit: | $-4.87M (-286.63 %) |
EPS: | $-1.200 |
Q4 | 2023 |
Revenue: | $1.78M |
Gross Profit: | $0 (0.00 %) |
EPS: | $-0.440 |
Q3 | 2023 |
Revenue: | $406 000 |
Gross Profit: | $24 000.00 (5.91 %) |
EPS: | $-0.260 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-1.51M (0.00 %) |
EPS: | $-0.260 |
Financial Reports:
No articles found.
Autolus Therapeutics PLC
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators